Descripción del proyecto
Un analgésico innovador derivado de compuestos marinos para el dolor crónico
El dolor crónico afecta a cien millones de personas solo en Europa, lo que lo convierte en una de las principales causas de discapacidad, con profundas repercusiones sobre la calidad de vida. Si bien los opiáceos son muy eficaces a la hora de tratar el dolor, conllevan el riesgo de adicción y otros efectos secundarios perjudiciales. La empresa biotecnológica Sea4Us ha desarrollado Sea4Pain, un fármaco innovador derivado de compuestos marinos. Sea4Pain podría ayudar a aliviar el sufrimiento de miles de millones de personas en todo el mundo. El proyecto Sea4Market, financiado por el Consejo Europeo de Innovación (CEI), tiene por objeto validar clínicamente Sea4Pain con ensayos en humanos y, a continuación, obtener la licencia de la tecnología para penetrar con rapidez en el mercado multimillonario del dolor crónico. El apoyo del CEI es fundamental para el éxito de esta iniciativa de alto riesgo y grandes recompensas.
Objetivo
Sea4Us is a world-class biotechnology company with a focus on translating marine-derived compounds with therapeutic potential for unmet medical needs into pharmaceutical assets. Sea4Us has developed a platform focused on drug discovery and development of novel pharmaceuticals based on its core expertise in ion channels and marine biology. Sea4Us is particularly focussed on developing and commercialising therapies for chronic pain.
Sea4Us has developed a ground-breaking therapeutic drug to treat chronic pain in patients. Chronic pain affects 100 million people across Europe, 1.6bn globally, and has a devastating impact on quality of life. Pain is the most common reason people visit their doctors and a leading cause of disability. It is a source of enormous social and economic burden, costing Europe alone over 500 billion Euros a year. There are many medications on the market for treating chronic pain, but they are either ineffective for most types of chronic pain and/or have adverse side-effects. Opioid drugs are the most effective treatment but also inflict drug addiction, habituation and other noxious side-effects. Our novel analgesic molecule, Sea4Pain, has a novel mechanism of action meaning it is highly effective at treating chronic pain and without any known side effects unlike current drugs on the market. Sea4Pain is a first-in-class drug and has the potential to ease the suffering of billions of people globally.
This EIC Accelerator project, called Sea4Market, will enable us to clinically validate our novel analgesic through completion of First-in-Human trials and out-license our technology to make a rapid entry into the multi-billion Euro Chronic Pain market. EIC support is essential to deliver this high-risk, high reward project and will enable the sustainable growth of our business. We will re-invest revenues from our licencing deal back into our project pipeline to solve other unmet medical needs and ensure the sustainable growth of our company.
Ámbito científico
Palabras clave
Programa(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Convocatoria de propuestas
HORIZON-EIC-2023-ACCELERATOR-01
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinador
8650-368 SAGRES
Portugal
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.